Good Morning all, It looks like the market is taking a beating today so I thought I would dedicate this post to one of our due diligence tools which is posting and posts on the various investor boards.
Somethings I want to explain to you about posts and posting are some of the various motives behind posting on the investor boards. Obviously one of the main reasons we post is to bring awareness to a particular stock. That is pretty much a given. I believe a good post creates awareness and includes information that can help you make your decision on whether to buy or sell the particular stock. For instance if I include a recent chart of a particular ticker in a post and also point out to you the highlights of that chart then that in my opinion is a good post that you can use in doing further due diligence on that ticker. My motive behind that post would be to give you some information that I myself would use in making a decision if I were going to trade that stock. A poster whos motive is to just pump a stock and create hype would of course think you are stupid and post something like "This stock is ready to move imo(in my opinion) 52 thousand times and clog up the board with this nonsense.
Predator promoters who just want to pump and dump a stock on a particular day will flood the posting boards with hundreds and hundreds of nonsensical posts just trying to get numbers for a day in order to make themselves look good. I am and have always been of the belief that quality always trumps quantity.
I do not ever post the same hype ridden post over and over again just trying to get my post numbers up. I believe you are intelligent and will recognize an intelligent informative post and do not need to be hounded with posts in order to make your decision on whether to invest or not.
Another motive behind posting is posters generally get hired to do just that. Post and post and more posting in order to just plain and simple get paid. On average posters get paid $1 per post with a minimum of 50 to 100 posts per day per promotion. I am not knocking getting paid to post as I get hired all of the time to post. What I am knocking is the blatant disregard for your intelligence when posts are being posted. For this reason my posts are always laced with content you can use and is designed to make you a more informed investor. So read all of those posts and find the posters who think along these lines and use that info to better make your decisions while doing as always your OWN due diligence in your investment decisions. Until tomorrow..... Ride Hard or Stay Home
Showing posts with label promoters. Show all posts
Showing posts with label promoters. Show all posts
Thursday, September 5, 2013
Monday, September 2, 2013
Beware Of Relying on Stock Technicals Alone
Good morning all,
Today I wanted to write a little about the dangers of relying on the technical aspects of stocks alone.
While technical analysis is a wonderful tool in determining the strength of a stock, it is not the end all to cure all in finding stocks to invest in.
Technical evaluations can have many hidden traps that pump and dump promoters place in there in an attempt to "dress" up whichever stock they are going to promote. Looking at price increases or decreases very rarely very accurate. Just because a stock finished the day at plus or minus a certain percentage doesnt mean it actually moved very well at all. To be clearer I have to actually look at the individual trades themselves and see the amounts that were bought or sold. Have you ever seen a big jump in a penny or sub penny stock and then looked and saw that it was a 50 share buy? That all to often is a promoters attempt to lure you into a stock on price alone. They manipulate the price with little buys thinking you wont notice that it was a crapola buy because they totally think you are stupid. A 100% gain on a stock is not really a gain if it only had 1,000 shares in volume. I say dig DEEPER.
Pay attention to the time and sales as promoters will manipulate the stock at 4 common times. The first is at the close the day before a promotion begins. They will often try to manipulate the stock down so as to get what they dress up and call a "bounce" first thing in the morning. The second is first thing in the morning in order to try to get the stock to move so they can proclaim its gaining momentum therefore luring you into their trap while at the same time making themselves look good. Third is once the stock stalls and we should all know by now that stocks stall. They will put in little buys in order to try to attract attention to the stock through percentage gains again creating another trap. The Fourth and in my book the most pathetic is the end of the day manipulation to save face because the promotion bombed. They will try to get an end of day percentage gain so that they can tout their followers with a look at what our "call" did today, It gained blah blah blah percentage.
Technicals can totally help you avoid these situations if you dig deeper underneath the dressed up surface, and also check to see if a particular stock has been promoted recently and what the outcome of that promotion was.
Until tomorrow,
Ride Hard or Stay Home
Sunday, January 27, 2013
Missing in action
Hey all. I know I have been missing in action for the last week and a half, Ive been busy setting up a new stock promotion team that consists of people like me who hate pump and dumps and gap and traps and promoters who could care less about you but instead care about their own bottom line.
Im talking about finding good quality companies with revenues and visions of long term growth. Companies that are NOT looking to dilute their stock and actually take an interest in their investors as well as their own growth. Fully reporting SEC compliant companies with full transparency. Products and Services that are real and a solid business plan. Sound too good to be true? I think NOT.
All it takes is a little due diligence. What Im talking about its ME doing the due diligence before I decide to let the company hire me. If I know going into a promotion what the company is all about then I can do my job for YOU and I can properly present that company to you. A good stock promoter puts a little buzz out a week or two before the promo and then on the day of the big campaign goes heavier getting the word out and then once its over gives 2 or 3 weeks more support to help keep the awareness and the price up.
I will keep you posted as I progress so you can watch the stocks we promote and see that while yes all stocks have bad days, ours dont just tank.
Im talking about finding good quality companies with revenues and visions of long term growth. Companies that are NOT looking to dilute their stock and actually take an interest in their investors as well as their own growth. Fully reporting SEC compliant companies with full transparency. Products and Services that are real and a solid business plan. Sound too good to be true? I think NOT.
All it takes is a little due diligence. What Im talking about its ME doing the due diligence before I decide to let the company hire me. If I know going into a promotion what the company is all about then I can do my job for YOU and I can properly present that company to you. A good stock promoter puts a little buzz out a week or two before the promo and then on the day of the big campaign goes heavier getting the word out and then once its over gives 2 or 3 weeks more support to help keep the awareness and the price up.
I will keep you posted as I progress so you can watch the stocks we promote and see that while yes all stocks have bad days, ours dont just tank.
Saturday, January 19, 2013
Dress me up and call me Sally
As Ive sat here all week watching certain unsuccessful stock promoters pump stocks endlessly and run the price up with their own 100 share buys, I thought about the poor investors who are just looking to have continual sustained long term growth in their portfolio and the actual companies who are having their stocks trashed by these promoters. You see most stock promotions are not run by the actual company but by third parties who have large positions in that stock looking to do one thing....... SELL
A vast majority of scams in the stock world are penny stocks. Alot of those stocks are just shell companies with no employees or products and absolutely no revenues at all. Promoters will dress up the presentation of those companies and try to lure you in on the promise of steady future growth when
actually after the days promotion the promoter will be long gone and you will be stuck in a stock worth
far less than you paid for it.
I think the best example I can give is from my own mistake I once made when I was young in my trading life. A promotional newsletter came out on a particular penny stock. I had a hot $1000 dollars burning a hole in my trading pocket and I wanted to trade it. So as I was getting pretty good at reading stockcharts I looked at the chart on the stock. Little did I know that the promoters had been "painting" the chart to make it look pretty for me as it called my name out.
On the day of the big promotion I woke excited as heck and already counting my extra thousands I was going to make as I had a hot tip newsletter that promised me fresh new news that was gonna make this sucker run. You see I made 3 very grave errors in my decision to trade this stock. First I believed the surface glitz they placed on the stock and didnt dig more on my own. Second I didnt have a position in it before the big "news" came out. Thirdly and probably most important is I was trading on emotion.
The stock traded hot and heavy for a hot 15 minutes and I had a hard time getting in because it gapped up . Once I finally got in, the stock fizzled and the downward spiral began. My 1000 dollars turned into
34 dollars as I was trapped in hoping for the readjustment bounce that never came. Eventually I was in so deep I just had to stay and refused to get out.
I have now filed that loss in the part of my education in stock trading file. Dont fall prey to the glam and glitz that got me. Do the work and reap the benefits of your hard work. Use the promoters alerts and newsletters only as a tool and not as your only decision maker in determining your investments.
My blog is my opinion and personal experiences only. Never EVER invest money you cant entirely afford to lose. As Always do your own due diligence
Tuesday, January 24, 2012
Keeping your emotions in check and your options open
Good Day all, I wanted to take a moment today to give you an example of keeping your emotions in check and your options open. Under normal circumstances most stocks that gap up or down at open fill that gap often during the first hour of trading. Trading solely on alerts or newsletters from promoters often lock you in during the volatile times and we risk getting wrapped up in the emotions we go through when we see our stock choice gapping up or down so quickly. For example yesterday MDCE gapped up 111% at the open after the promoter promoting it announced days prior that the ticker announcement would be after the opening bell to avoid such a gap. That open was at best fishy and a total trap.
7 minutes after the big ticker announcement the stock plummeted down 35% from its open and then 4 minutes later it was down another 53% and ended up closing up 35%. A huge trap for those less than savvy traders, as most seeing the initial gap up would think OMG I have to get on this train before it leaves the station and then would have lost their butts in this classic Gap and Trap farce. This stock never was even close to the 50 day moving avg, so I would have never gotten in this one.
This is why unless I have my position prior to open I never ever get in during that first hour as this stock never recovered to its high of the day (HOD) and if id tried to get in after open unless I was shorting the stock I would have lost my butt.
So keep your emotions in check and be patient. If you miss out on this one there is always the next one.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
7 minutes after the big ticker announcement the stock plummeted down 35% from its open and then 4 minutes later it was down another 53% and ended up closing up 35%. A huge trap for those less than savvy traders, as most seeing the initial gap up would think OMG I have to get on this train before it leaves the station and then would have lost their butts in this classic Gap and Trap farce. This stock never was even close to the 50 day moving avg, so I would have never gotten in this one.
This is why unless I have my position prior to open I never ever get in during that first hour as this stock never recovered to its high of the day (HOD) and if id tried to get in after open unless I was shorting the stock I would have lost my butt.
So keep your emotions in check and be patient. If you miss out on this one there is always the next one.
Thursday, January 12, 2012
Promoterese 101
I received an interesting alert from a predator promoter group who thought they could just change their spots (name) and all the people they left holding bags would be none the smarter. After many months of telling the former mentioned promoter that not all of their plays should be paid,and that its good to profile stocks for free in order to give their followers a fighting chance at trusting them they balked. So low and behold the great white knight has come up with a free promotion. Many red flags are raised just by the deceptive wording of the alert :
This company is at ground zero of one of the biggest market stories of the decade. This is where the story gets juicy.
This company has positioned themselves in a much better Price per share area to attract investors and not just flippers. The current sector is already estimated at over $100 Billion, and with a projected 30 Million new customers coming into this sector in the next 10 years.
This company is showing us a strong Commitment to growth and seems to have the fundamentals that could keep them a major player in this industry for time to come!
My first problem with this deceptive alert is that it is a sub-penny stock. With the current SEC movement to rid the market of penny and sub penny stocks, a company actually positioning itself in a sub penny category is a farce and if in fact it is true then just downright ridiculous. Next is the creative wording the promoter uses... already estimated, and with a projected, seems to have the fundamentals that COULD. These are all deceptive twists intended to lure you into the hype of yet again another dog. Wanna know why its a free promo? Because the company has no money. It is actually most likely a tryout for the promoter to try to impress a third party who has a large position in it that they are good and are worthy of their business of deceiving you!! Plays like this also tend to be front loaded largely by the promoters cronies that they alert ahead of the play and those cronies will dump the stock as you buy in. Dont be duped by the Promoterese!!
This company is at ground zero of one of the biggest market stories of the decade. This is where the story gets juicy.
This company has positioned themselves in a much better Price per share area to attract investors and not just flippers. The current sector is already estimated at over $100 Billion, and with a projected 30 Million new customers coming into this sector in the next 10 years.
This company is showing us a strong Commitment to growth and seems to have the fundamentals that could keep them a major player in this industry for time to come!
My first problem with this deceptive alert is that it is a sub-penny stock. With the current SEC movement to rid the market of penny and sub penny stocks, a company actually positioning itself in a sub penny category is a farce and if in fact it is true then just downright ridiculous. Next is the creative wording the promoter uses... already estimated, and with a projected, seems to have the fundamentals that COULD. These are all deceptive twists intended to lure you into the hype of yet again another dog. Wanna know why its a free promo? Because the company has no money. It is actually most likely a tryout for the promoter to try to impress a third party who has a large position in it that they are good and are worthy of their business of deceiving you!! Plays like this also tend to be front loaded largely by the promoters cronies that they alert ahead of the play and those cronies will dump the stock as you buy in. Dont be duped by the Promoterese!!
Wednesday, January 11, 2012
I think its important that I show you what a good Due Diligence piece looks like so Ive put together a piece on a bio company so you can see the pertinent information that I look for when Im searching a company.
Curis, Inc.~ Nasdaq Bio~ CRIS due diligence
CRIS Company Overview & Description
Curis, Inc is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at http://www.curis.com
CRIS Corporate Fact Sheet: http://www.curis.com/Corp_Fact_Sheet_2011.pdf
CRIS Corporate Overview Presentation: http://www.curis.com/Corporate_Overview.pdf
CRIS Key Company Management
Daniel R. Passeri
President and Chief Executive Officer
Mr. Passeri has served as our President and Chief Executive Officer and as a director since September 2001. From November 2000 to September 2001, Mr. Passeri served as Senior Vice President, Corporate Development and Strategic Planning of the Company. From March 1997 to November 2000, Mr. Passeri was employed by GeneLogic Inc., a biotechnology company, most recently as Senior Vice President, Corporate Development and Strategic Planning. From February 1995 to March 1997, Mr. Passeri was employed by Boehringer Mannheim, a pharmaceutical, biotechnology and diagnostic company, as Director of Technology Management. Mr. Passeri is a graduate of the National Law Center at George Washington University, with a J.D., of the Imperial College of Science, Technology and Medicine at the University of London, with an M.Sc. in biotechnology, and of Northeastern University, with a B.S. in biology.
Maurizio Voi, M.D.
Chief Medical and Chief Development Officer
Dr. Voi has served as our Chief Medical and Chief Development Officer since November 2011. From October 2009 until November 2011, Dr. Voi was employed by Pfizer as Vice President of Clinical Development and Medical Affairs at the Oncology Business Unit of Pfizer’s Global Research and Development site in New York. Dr. Voi joined Pfizer as Thoracic Tumor Strategy Team Leader for Oncology. In this role, he was responsible for developing strategic plans for assets within the Pfizer portfolio for the treatment of thoracic cancers, with a special emphasis on identifying patient populations most likely to respond to targeted agents by concurrently developing compounds and diagnostics, including XALKORI® (crizotinib), an ALK inhibitor for the treatment of ALK+ advanced non-small cell lung cancer that was granted FDA approval in 2011. Prior to joining Pfizer, Dr. Voi served from 1998 to 2009 in several key positions at Bristol-Myers Squibb Company, most recently as the Executive Director, Global Clinical Development and Medical Affairs, Oncology, where he was instrumental in the development and regulatory submission and approval of Sprycel® in chronic myelogenous leukemia as well as in supplemental BLA’s of Erbitux® in colorectal, non-small cell lung and head and neck cancers. From 1987-1999, he served in several roles at Eli Lilly and Company, where he was involved in preparing the registration dossier for a regulatory approval filing in non-small cell lung cancer of Gemzar® in Europe as well as ultimately assuming responsibility for Gemzar® worldwide development and commercialization.
Dr. Voi received his medical degree from the University of Padua, School of Medicine Italy and practiced medicine at the General Hospital, Dolo in Venice, Italy.
Michael P. Gray
Chief Operating and Chief Financial Officer
Mr. Gray has served as our Chief Operating Officer and Chief Financial Officer since December 2006. From December 2003 until December 2006, Mr. Gray served as our Vice President of Finance and Chief Financial Officer and served as our Senior Director of Finance and Controller from August 2000 until December 2003. Mr. Gray held financial positions including Controller and de Facto Chief Financial Officer at Reprogenesis, a predecessor biotechnology company, from January 1998 until July 2000. Mr. Gray previously served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray is a certified public accountant, holds an M.B.A. from the F.W. Olin Graduate School of Business at Babson College, and has a B.S. in accounting from Bryant College.
Changgeng Qian, Ph.D., M.D.
Senior Vice President, Discovery and Preclinical Development
Dr. Qian joined Curis in 2001. He has over 30 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. Prior to Curis, he played a key role in the discovery of several anti-inflammation, anticancer and CNS drug candidates at CytoMed Inc., LeukoSite Inc., and Millennium Pharmaceuticals, Inc. He is an inventor on more than 10 issued U.S. patents and over 25 published PCT patents and has authored approximately 30 scientific publications. Dr. Qian earned a Ph.D. in Pharmacology and an M.D. from the Hunan Medical University and has served as a professor of the University since 1992.
Mark Noel
Vice President, Technology Management and Intellectual Property
Mr. Noel has served as our Vice President, Technology Management and Intellectual Property since September 2008. From March 2001 until September 2008, Mr. Noel served as our Vice President, Technology Management and Business Development. From March 2000 to February 2001, Mr. Noel was employed by GeneLogic, as Vice President of Customer Relations. From January 1998 to February 2000, Mr. Noel was employed by GeneLogic as Senior Director of Program Management. From December 1993 to January 1998, Mr. Noel was employed by the National Cancer Institute’s Office of Technology Development (now the Technology Transfer Branch of the NCI Office of Technology and Industrial Relations), where from July 1997 to January 1998, he served as Acting Deputy Director. From February 1989 to November 1993, Mr. Noel worked as a patent agent at Gist Brocades NV, a supplier of ingredients to the pharmaceutical and food sectors. Mr. Noel holds a B.S. from the University of Maryland.
CRIS Contact Info
Curis Inc. Corporate Headquarters
4 Maguire Road
Lexington, MA 02421
Tel: [617] 503-6500
Fax: [617] 503-6501
Website: http://www.curis.com
Email Alert Subscription: http://investors.curis.com/alerts.cfm?
Contact IR
Curis, Inc.
4 Maguire Road
Lexington, MA 02421
Phone: 617-503-6500
E-mail: info@curis.com
CRIS Recent Developments
SEC Filings
http://finance.yahoo.com/q/sec?s=CRIS+SEC+Filings
Competitors
http://finance.yahoo.com/q/co?s=CRIS+Competitors
Industry
http://finance.yahoo.com/q/in?s=CRIS+Industry
Headlines
http://finance.yahoo.com/q/h?s=CRIS+Headlines
Current Corporate Collaborators
Collaborator Program Disease
Genentech (vismodegib) Hedgehog Pathway Inhibitor Cancer
Debiopharm SA (Debio 0932) Debio 0932 (Hsp90 inhibitor; formerly CUDC-305) Cancer
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech completed an NDA submission with the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
http://www.curis.com/collaborations_detail.php?collaborationid=1
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing.
http://www.curis.com/collaborations_detail.php?collaborationid=7
CRIS Products & Services
Over the past several years, targeted cancer drugs have been considered among the most promising cancer treatments for obtaining a therapeutic effect with less toxicity when compared with traditional chemotherapy, which, in addition to attacking cancerous cells, also tends to attack a broad range of healthy cells. A large body of published data shows cancers to have multiple, intersecting signaling pathways that support survival, growth, and invasion. Targeting only one or two of these pathways with single-targeted agents has generally only led to modest improvements to existing standards-of-care and most cancer patients with solid tumors do not respond in a clinically meaningful manner. Targeting the correct combination of critical signaling pathways within the network of cancer cell signaling pathways could provide a major improvement in outcomes for cancer patients and is an area of intense research and development.
Curis is utilizing medicinal chemistry and biological expertise to develop a series of proprietary targeted cancer drug programs. These programs focus on the development of single-agent drug candidates targeting one or more molecular components within the signaling pathways associated with certain cancers. These programs are primarily focused on developing a number of proprietary, small molecule, single-agent, multi-targeted inhibitor drug compounds. Each proprietary compound is being designed to inhibit biologically- or clinically-validated cancer targets, including, among others, EGFR, Her2, Bcr-Abl tyrosine kinase and phosphatidylinositol-3-kinase (PI3k), in combination with inhibition of HDAC, which is a validated non-kinase cancer target. Curis is also seeking to use this platform to develop proprietary, differentiated, single-agent, single-target drug candidates for cancer indications.
HDAC inhibition is a core component in each of Curis’ multi-targeted inhibitors. Curis believes that HDAC is a promising non-kinase target for cancer therapy, particularly when combined with simultaneous inhibition of certain other targets. There is substantial preclinical evidence of synergistic induction of cancer cell death when HDAC inhibitors are combined with a diverse range of other targeted therapies or standard chemotherapeutic agents, demonstrating that HDAC inhibition may be more broadly effective in the treatment of cancer when integrated with other inhibitory activities.
Currently, there are two Food and Drug Administration, or FDA, approved HDAC inhibitors and several other HDAC-targeted drug candidates in clinical trials for cancer.
In furtherance of the development of Curis’ targeted cancer programs, the Company outsources certain medicinal chemistry and other preclinical functions with contract research organizations in China. Curis has developed these relationships with Chinese providers to support its U.S. operations and Curis is currently engaging approximately 25 chemists in China. Curis’ drug discovery efforts utilize significant medicinal chemistry resources. The Company’s management believes that these relationships have been important to Curis’ efforts to create a broad portfolio of proprietary cancer drugs by generating several classes of compounds for further development in a cost-effective manner.
Curis filed a number of patents including a broad omnibus patent application that covers the drug design concept that is the basis for the multi-targeted cancer programs, as well as numerous species filings relating to specific classes of compounds which Curis believes will constitute novel compositions from a patentability standpoint. Curis expects that it will continue to file additional patent applications covering new compositions in the future.
CUDC-101, Curis’ first drug candidate from our targeted cancer programs, is being designed as a multi-target inhibitor of HDAC, EGFR and Her2 and is currently the subject of a phase Ib expansion clinical trial as well as a Phase I trial in head and neck cancer in combination with radiation and cisplatin. Curis is also developing CUDC-907, a PI3K/HDAC inhibitor and expects that it will submit an IND for this molecule in early 2012. In August, 2009 Curis licensed its first single-agent, single-target inhibitor drug candidate, CUDC-305 (now Debio 0932), an Hsp90 inhibitor to Debiopharm. Curis researchers are continuing to investigate other classes of compounds in an effort to advance additional compounds into clinical development.
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech submitted a New Drug Application (NDA) to the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase Ib clinical testing.
Curis also recently selected orally-available PI3K/HDAC inhibitor CUDC-907 as a development candidate and expects to begin Phase I clinical testing with this molecule in early 2012.
Curis has focused most of its internal resources on developing additional small molecule targeted cancer drug candidates. Curis completed a Phase I clinical trial of CUDC-101, a first-in-class inhibitor of EGFR, Her2 and HDAC, in the first half of 2010. The Company also initiated in August 2010 a Phase Ib expansion trial of this molecule in patients with breast, gastric, head and neck, liver and non-small cell lung cancers and in August 2011 initiated a Phase I clinical trial in HPV- locally advanced head and neck cancer in combination with standard-of-care treatment (cisplatin and radiation).
In addition, Curis has several programs that are in various stages of preclinical drug development. Because of the early stages of development of these programs, its ability and that of the Company's collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain.
Financial Reporting/Disclosure & Security Details
Shareholders tools: http://investors.curis.com/
CRIS follows under these quidelines on the Nasdaq market tier.
Investigate more @ http://www.otcmarkets.com/stock/CRIS/quote for more due diligence.
Share Structure
Market Cap. (Mil) $336.19
Shares Out (Mil)76.58
Float (Mil)56.84
Share Related information provided by MorningStar, Inc.
Data as of Jan 9, 2012.
Mil=Millions
watch updates here: http://investors.curis.com/financials.cfm
Par Value: .01
Shareholders
Shareholders of Record: 76
Transfer Agent(s)
BNY Mellon Shareowner Services
P.O. Box 358015
85 Challenger Road
Pittsburgh, PA 15252-8015
Phone: 877.810.2248
TA Corporate Website: http://www.bnymellon.com/shareowner/isd
Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
OTC Disclosure last 10Q reported Oct 31, 2011 period ending Sept 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8212490
OTC Disclosure last 10K reported Mar 8, 2011 period ending Dec 31, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7783210
CIK: 0001108205
Fiscal Year End: 12/31
OTC Market Tier: Nasdaq
Profile Data
SIC - Industry Classification: CURIS, INC. - SIC # 2836
Sector: HealthCare
Industry: Biotechnology
Incorporated In: DE, USA
Year of Inc:
Employees: 32
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CRIS website
(CRIS website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.)
Curis, Inc.~ Nasdaq Bio~ CRIS due diligence
CRIS Company Overview & Description
Curis, Inc is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at http://www.curis.com
CRIS Corporate Fact Sheet: http://www.curis.com/Corp_Fact_Sheet_2011.pdf
CRIS Corporate Overview Presentation: http://www.curis.com/Corporate_Overview.pdf
Daniel R. Passeri
President and Chief Executive Officer
Mr. Passeri has served as our President and Chief Executive Officer and as a director since September 2001. From November 2000 to September 2001, Mr. Passeri served as Senior Vice President, Corporate Development and Strategic Planning of the Company. From March 1997 to November 2000, Mr. Passeri was employed by GeneLogic Inc., a biotechnology company, most recently as Senior Vice President, Corporate Development and Strategic Planning. From February 1995 to March 1997, Mr. Passeri was employed by Boehringer Mannheim, a pharmaceutical, biotechnology and diagnostic company, as Director of Technology Management. Mr. Passeri is a graduate of the National Law Center at George Washington University, with a J.D., of the Imperial College of Science, Technology and Medicine at the University of London, with an M.Sc. in biotechnology, and of Northeastern University, with a B.S. in biology.
Maurizio Voi, M.D.
Chief Medical and Chief Development Officer
Dr. Voi has served as our Chief Medical and Chief Development Officer since November 2011. From October 2009 until November 2011, Dr. Voi was employed by Pfizer as Vice President of Clinical Development and Medical Affairs at the Oncology Business Unit of Pfizer’s Global Research and Development site in New York. Dr. Voi joined Pfizer as Thoracic Tumor Strategy Team Leader for Oncology. In this role, he was responsible for developing strategic plans for assets within the Pfizer portfolio for the treatment of thoracic cancers, with a special emphasis on identifying patient populations most likely to respond to targeted agents by concurrently developing compounds and diagnostics, including XALKORI® (crizotinib), an ALK inhibitor for the treatment of ALK+ advanced non-small cell lung cancer that was granted FDA approval in 2011. Prior to joining Pfizer, Dr. Voi served from 1998 to 2009 in several key positions at Bristol-Myers Squibb Company, most recently as the Executive Director, Global Clinical Development and Medical Affairs, Oncology, where he was instrumental in the development and regulatory submission and approval of Sprycel® in chronic myelogenous leukemia as well as in supplemental BLA’s of Erbitux® in colorectal, non-small cell lung and head and neck cancers. From 1987-1999, he served in several roles at Eli Lilly and Company, where he was involved in preparing the registration dossier for a regulatory approval filing in non-small cell lung cancer of Gemzar® in Europe as well as ultimately assuming responsibility for Gemzar® worldwide development and commercialization.
Dr. Voi received his medical degree from the University of Padua, School of Medicine Italy and practiced medicine at the General Hospital, Dolo in Venice, Italy.
Michael P. Gray
Chief Operating and Chief Financial Officer
Mr. Gray has served as our Chief Operating Officer and Chief Financial Officer since December 2006. From December 2003 until December 2006, Mr. Gray served as our Vice President of Finance and Chief Financial Officer and served as our Senior Director of Finance and Controller from August 2000 until December 2003. Mr. Gray held financial positions including Controller and de Facto Chief Financial Officer at Reprogenesis, a predecessor biotechnology company, from January 1998 until July 2000. Mr. Gray previously served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray is a certified public accountant, holds an M.B.A. from the F.W. Olin Graduate School of Business at Babson College, and has a B.S. in accounting from Bryant College.
Changgeng Qian, Ph.D., M.D.
Senior Vice President, Discovery and Preclinical Development
Dr. Qian joined Curis in 2001. He has over 30 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. Prior to Curis, he played a key role in the discovery of several anti-inflammation, anticancer and CNS drug candidates at CytoMed Inc., LeukoSite Inc., and Millennium Pharmaceuticals, Inc. He is an inventor on more than 10 issued U.S. patents and over 25 published PCT patents and has authored approximately 30 scientific publications. Dr. Qian earned a Ph.D. in Pharmacology and an M.D. from the Hunan Medical University and has served as a professor of the University since 1992.
Mark Noel
Vice President, Technology Management and Intellectual Property
Mr. Noel has served as our Vice President, Technology Management and Intellectual Property since September 2008. From March 2001 until September 2008, Mr. Noel served as our Vice President, Technology Management and Business Development. From March 2000 to February 2001, Mr. Noel was employed by GeneLogic, as Vice President of Customer Relations. From January 1998 to February 2000, Mr. Noel was employed by GeneLogic as Senior Director of Program Management. From December 1993 to January 1998, Mr. Noel was employed by the National Cancer Institute’s Office of Technology Development (now the Technology Transfer Branch of the NCI Office of Technology and Industrial Relations), where from July 1997 to January 1998, he served as Acting Deputy Director. From February 1989 to November 1993, Mr. Noel worked as a patent agent at Gist Brocades NV, a supplier of ingredients to the pharmaceutical and food sectors. Mr. Noel holds a B.S. from the University of Maryland.
Curis Inc. Corporate Headquarters
4 Maguire Road
Lexington, MA 02421
Tel: [617] 503-6500
Fax: [617] 503-6501
Website: http://www.curis.com
Email Alert Subscription: http://investors.curis.com/alerts.cfm?
Contact IR
Curis, Inc.
4 Maguire Road
Lexington, MA 02421
Phone: 617-503-6500
E-mail: info@curis.com
SEC Filings
http://finance.yahoo.com/q/sec?s=CRIS+SEC+Filings
Competitors
http://finance.yahoo.com/q/co?s=CRIS+Competitors
Industry
http://finance.yahoo.com/q/in?s=CRIS+Industry
Headlines
http://finance.yahoo.com/q/h?s=CRIS+Headlines
Collaborator Program Disease
Genentech (vismodegib) Hedgehog Pathway Inhibitor Cancer
Debiopharm SA (Debio 0932) Debio 0932 (Hsp90 inhibitor; formerly CUDC-305) Cancer
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech completed an NDA submission with the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
http://www.curis.com/collaborations_detail.php?collaborationid=1
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing.
http://www.curis.com/collaborations_detail.php?collaborationid=7
Over the past several years, targeted cancer drugs have been considered among the most promising cancer treatments for obtaining a therapeutic effect with less toxicity when compared with traditional chemotherapy, which, in addition to attacking cancerous cells, also tends to attack a broad range of healthy cells. A large body of published data shows cancers to have multiple, intersecting signaling pathways that support survival, growth, and invasion. Targeting only one or two of these pathways with single-targeted agents has generally only led to modest improvements to existing standards-of-care and most cancer patients with solid tumors do not respond in a clinically meaningful manner. Targeting the correct combination of critical signaling pathways within the network of cancer cell signaling pathways could provide a major improvement in outcomes for cancer patients and is an area of intense research and development.
Curis is utilizing medicinal chemistry and biological expertise to develop a series of proprietary targeted cancer drug programs. These programs focus on the development of single-agent drug candidates targeting one or more molecular components within the signaling pathways associated with certain cancers. These programs are primarily focused on developing a number of proprietary, small molecule, single-agent, multi-targeted inhibitor drug compounds. Each proprietary compound is being designed to inhibit biologically- or clinically-validated cancer targets, including, among others, EGFR, Her2, Bcr-Abl tyrosine kinase and phosphatidylinositol-3-kinase (PI3k), in combination with inhibition of HDAC, which is a validated non-kinase cancer target. Curis is also seeking to use this platform to develop proprietary, differentiated, single-agent, single-target drug candidates for cancer indications.
HDAC inhibition is a core component in each of Curis’ multi-targeted inhibitors. Curis believes that HDAC is a promising non-kinase target for cancer therapy, particularly when combined with simultaneous inhibition of certain other targets. There is substantial preclinical evidence of synergistic induction of cancer cell death when HDAC inhibitors are combined with a diverse range of other targeted therapies or standard chemotherapeutic agents, demonstrating that HDAC inhibition may be more broadly effective in the treatment of cancer when integrated with other inhibitory activities.
Currently, there are two Food and Drug Administration, or FDA, approved HDAC inhibitors and several other HDAC-targeted drug candidates in clinical trials for cancer.
In furtherance of the development of Curis’ targeted cancer programs, the Company outsources certain medicinal chemistry and other preclinical functions with contract research organizations in China. Curis has developed these relationships with Chinese providers to support its U.S. operations and Curis is currently engaging approximately 25 chemists in China. Curis’ drug discovery efforts utilize significant medicinal chemistry resources. The Company’s management believes that these relationships have been important to Curis’ efforts to create a broad portfolio of proprietary cancer drugs by generating several classes of compounds for further development in a cost-effective manner.
Curis filed a number of patents including a broad omnibus patent application that covers the drug design concept that is the basis for the multi-targeted cancer programs, as well as numerous species filings relating to specific classes of compounds which Curis believes will constitute novel compositions from a patentability standpoint. Curis expects that it will continue to file additional patent applications covering new compositions in the future.
CUDC-101, Curis’ first drug candidate from our targeted cancer programs, is being designed as a multi-target inhibitor of HDAC, EGFR and Her2 and is currently the subject of a phase Ib expansion clinical trial as well as a Phase I trial in head and neck cancer in combination with radiation and cisplatin. Curis is also developing CUDC-907, a PI3K/HDAC inhibitor and expects that it will submit an IND for this molecule in early 2012. In August, 2009 Curis licensed its first single-agent, single-target inhibitor drug candidate, CUDC-305 (now Debio 0932), an Hsp90 inhibitor to Debiopharm. Curis researchers are continuing to investigate other classes of compounds in an effort to advance additional compounds into clinical development.
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech submitted a New Drug Application (NDA) to the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase Ib clinical testing.
Curis also recently selected orally-available PI3K/HDAC inhibitor CUDC-907 as a development candidate and expects to begin Phase I clinical testing with this molecule in early 2012.
Curis has focused most of its internal resources on developing additional small molecule targeted cancer drug candidates. Curis completed a Phase I clinical trial of CUDC-101, a first-in-class inhibitor of EGFR, Her2 and HDAC, in the first half of 2010. The Company also initiated in August 2010 a Phase Ib expansion trial of this molecule in patients with breast, gastric, head and neck, liver and non-small cell lung cancers and in August 2011 initiated a Phase I clinical trial in HPV- locally advanced head and neck cancer in combination with standard-of-care treatment (cisplatin and radiation).
In addition, Curis has several programs that are in various stages of preclinical drug development. Because of the early stages of development of these programs, its ability and that of the Company's collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain.
Shareholders tools: http://investors.curis.com/
CRIS follows under these quidelines on the Nasdaq market tier.
Investigate more @ http://www.otcmarkets.com/stock/CRIS/quote for more due diligence.
Share Structure
Market Cap. (Mil) $336.19
Shares Out (Mil)76.58
Float (Mil)56.84
Share Related information provided by MorningStar, Inc.
Data as of Jan 9, 2012.
Mil=Millions
watch updates here: http://investors.curis.com/financials.cfm
Par Value: .01
Shareholders
Shareholders of Record: 76
Transfer Agent(s)
BNY Mellon Shareowner Services
P.O. Box 358015
85 Challenger Road
Pittsburgh, PA 15252-8015
Phone: 877.810.2248
TA Corporate Website: http://www.bnymellon.com/shareowner/isd
Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
OTC Disclosure last 10Q reported Oct 31, 2011 period ending Sept 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8212490
OTC Disclosure last 10K reported Mar 8, 2011 period ending Dec 31, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7783210
CIK: 0001108205
Fiscal Year End: 12/31
OTC Market Tier: Nasdaq
Profile Data
SIC - Industry Classification: CURIS, INC. - SIC # 2836
Sector: HealthCare
Industry: Biotechnology
Incorporated In: DE, USA
Year of Inc:
Employees: 32
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CRIS website
(CRIS website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.)
As you can see this is NOT a penny or subpenny stock. I stay away from those as that is where most of the predator promoters and third parties who are looking for you to hold their bags are. Until tomorrow....
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Monday, January 9, 2012
Pump and Dump failure
Hey everyone. I had to take off a few days with a kidney infection but Im back as good as new. So did anyone catch the pump and dump failure of BRKM on thursday? After the big hype a certain flailing promoter put out on tuesday about preventing a big gap up by not announcing the ticker until after the bell opened, they postponed the ticker announcement until thursday and then proceeded to start pumping it on wednesday evening prior to thursdays open. The stock gapped up 17% then started a day long free fall that never recovered. Now if you got caught up in the hype and was left holding the bag, heres the negative due diligence that I uncovered with a little bit of digging:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8274281
OTC Disclosure last 10Q reported ___ period ending ___
On October 7, 2010 the Company, as Book Merge Technology, Inc, (BMT), entered into a plan of reorganization with a private company, Extreme Green Technologies Inc. (EGT). A reverse merger was effected on October 11, 2010, wherein BMT, (then a shell), was the surviving company and legal acquirer whereas EGT was the operating company. Accordingly, operations of the entity are reported as those of the original EGT, the operating company. BMT subsequently changed its name to Extreme Green Technologies, Inc., on August 12, 2011.
why hasnt it been updated anywhere???
a hole
weeeeeeeeeeeee
line 10 of 10Q
Common Stock
On September 1, 2011, 10,000,000 shares of common stock were issued in reducing the deferred investment loans by $10,000.
Shareholders of Record 235 a/o Nov 15, 2011
The promoter didnt even have the correct information about the share structure and float which I easily obtained by contacting the transfer agent. I highlighted one of my number one red flags in the comapany description which is...... Our mission is to..... which means we arent really doing anything but we want to..... The last promotion this company had one of the owners accounted for 50% of the stock sold during the promotion.... Can you say DILUTION? On a sinking ship, the first ones to jump off are the RATS. The float the promoter listed was a mere 10 million less than the actual float which is a pretty significant difference when trying to attract investors. What I am getting at again is.... dont trust every alert or shined up due diligence piece you see. Scrutinize it yourself and see the differences in the actual due diligence and what the promoter is putting out. Dont buy the smoke and mirrors! Until tomorrow have an awesome day!
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
according to this map its a vacant lot???
http://www.loopnet.com/Property-Record/1560-N-Maple-Street-Corona-CA-92880/Yfb5Kim2g/Maps/
according to google the closest address to be found is 1260 and if you follow it down, 1557 is the last on the street
this site lists it as an automotive place: yellow pages
http://yellowpages.superpages.com/bp/Corona-CA/Automotive-Appearance-Specialists-L2189463242.htm
this one lists it as the content company
http://www.merchantcircle.com/business/The.Contents.Company.951-371-8106
Categories: Home & Garden | Home Repair & Improvement | Fire & Water Damage
Tags: building, restoration, preservation, corona,
http://start.cortera.com/company/research/k3m7qvr0s/r--j-leathercraft/
must be an office space but known the less
maybe frontloading?
Stock and Tier: BRKM QB per otc
does the company have a stockchart available?:
yes
http://www.nasdaq.com/
what is this stocks record volume:
avg daily volume: 108k
52 week high volume:
http://www.otcmarkets.com/stock/BRKM/insider-transactions
half of days volume was this guy selling
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7909547
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180462
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68483438&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67138322&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64259821&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180610&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180321&txt2find=steve|hayden
http://hot-news.posterous.com/?tag=entkpk
52 week low:
has this stock been promoted? http://newsletter.hotstocked.com/stocks
http://newsletter.hotstocked.com/stocks/view
http://newsletter.hotstocked.com/stocks/view/BRKM-BOOKMERGE-TECHNOLOGY
last promoted in june
was .22 in may when promoted and ran down ever since
BRKM turns trash into fuel for 840% revenue growth!Jun 22, 2011 08:10
http://www.otcmarkets.com
business description
BookMerge Technology is an alternative fuel and recycling company. Our mission is to provide a cost-effective, high-quality alternative diesel fuel, create "green" jobs, reduce the environmental impact of fossil fuels and diminish US reliance on foreign oil. On November 29, 2010 BookMerge aquired ExtremeGreen Technologies, Inc. dba Extreme Biodiesel to fulfill that mission. Extreme Biodiesel is a fully licensed and permitted Biodiesel producer operating in Corona, CA. Our facility has been an operating since January 2008, producing Biodiesel fuel (diesel fuel made from waste vegetable we collect), manufacturing personal biodiesel processors, and the recently added restaurant brown grease recycling service.
The correct float from the transfer agent is:
http://www.loopnet.com/Property-Record/1560-N-Maple-Street-Corona-CA-92880/Yfb5Kim2g/Maps/
according to google the closest address to be found is 1260 and if you follow it down, 1557 is the last on the street
this site lists it as an automotive place: yellow pages
http://yellowpages.superpages.com/bp/Corona-CA/Automotive-Appearance-Specialists-L2189463242.htm
this one lists it as the content company
http://www.merchantcircle.com/business/The.Contents.Company.951-371-8106
Categories: Home & Garden | Home Repair & Improvement | Fire & Water Damage
Tags: building, restoration, preservation, corona,
http://start.cortera.com/company/research/k3m7qvr0s/r--j-leathercraft/
must be an office space but known the less
maybe frontloading?
Stock and Tier: BRKM QB per otc
does the company have a stockchart available?:
yes
http://www.nasdaq.com/
what is this stocks record volume:
| 04/29/2011 | 0.1 | 0.22 | 0.09 | 0.15 | 2,228,041 |
avg daily volume: 108k
52 week high volume:
| 04/29/2011 | 0.1 | 0.22 | 0.09 | 0.15 | 2,228,041 |
| Apr 29, 2011 | HAYDEN STEVE Beneficial Owner (10%) | direct | Sell | 0.095 | 1,018,841 |
http://www.otcmarkets.com/stock/BRKM/insider-transactions
half of days volume was this guy selling
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7909547
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180462
Steve Hayden is involved in this, that means its not going to go good for the investor once he gets out. I notice BRKM has Extreme Biodiesel, a former part of Envirotek. That was a bad company then, and it is now. They are actually re releasing old ENTK press as new BRKM press.
june 2011
june 2011
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68483438&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67138322&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64259821&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180610&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180321&txt2find=steve|hayden
http://hot-news.posterous.com/?tag=entkpk
52 week low:
| 12/12/2011 | 0.01 | 0.01 | 0.007 | 0.0099 | 144,000 |
has this stock been promoted? http://newsletter.hotstocked.com/stocks
http://newsletter.hotstocked.com/stocks/view
http://newsletter.hotstocked.com/stocks/view/BRKM-BOOKMERGE-TECHNOLOGY
last promoted in june
was .22 in may when promoted and ran down ever since
BRKM turns trash into fuel for 840% revenue growth!Jun 22, 2011 08:10
BRKM Announces 840% Increase in Revenue for Q4 2011, After 400% Revenue Jump Previously Announced for Q1 2011! Extreme Biodiesel is a wholly-owned Corona, California-based Bookmerge Technology, Inc subsidiary involved with the development, marketing, and commercialization of bulk bio-diesel fuel, personal biodiesel processors, and related products. Extreme Biodiesel currently operates primarily in the state of California, but provides ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$15,000 | 49,803 | |
Max Profit: 3.78 % | Gain at close: -0.67 % |
(YOU) Must read before 10PM - Doubting Me Could Cost Ya HugeJun 15, 2011 20:48Research Driven InvestorBy David Cohen 6/15/2011 Why RDI? David Cohen, Editor and Publisher of the Research Driven Investor, now ranked as one of the top five performing micro-cap investment newsletters in America from 2003 to 2009. David Cohen reveals penny stocks with: proven management teams, increasing market share, ballooning revenues,low debt loads, improving financial ratios ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$40,000 | UNKNOWN | |
Max Profit: 7.14 % | Gain at close: 7.14 % |
BRKM Can It Triple - (Open Fast)Jun 15, 2011 16:07Research Driven InvestorBy David Cohen 6/15/2011 Why RDI? David Cohen, Editor and Publisher of the Research Driven Investor, now ranked as one of the top five performing micro-cap investment newsletters in America from 2003 to 2009. David Cohen reveals penny stocks with: proven management teams, increasing market share, ballooning revenues,low debt loads, improving financial ratios ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$40,000 | 64,037 | |
Max Profit: 7.14 % | Gain at close: 7.14 % |
Past History Shows BRKM Has Explosive Potential!May 20, 2011 07:32 BookMerge Technology, Inc. - BRKM Past History Shows BRKM Has Explosive Potential! BRKM is an alternative fuel and recycling company whose mission is to provide a cost effective, high quality alternative diesel fuel, create Green Jobs, reduce the environmental impact of fossil fuels and diminish U.S. reliance on foreign oil. This mission statement has so much good stuff in it I don̢۪t ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$7,500 | 24,387 | |
Max Profit: 0.06 % | Gain at close: -6.19 % |
Past History Shows BRKM Has Explosive Potential!May 20, 2011 07:22 BookMerge Technology, Inc. - BRKM Past History Shows BRKM Has Explosive Potential! BRKM is an alternative fuel and recycling company whose mission is to provide a cost effective, high quality alternative diesel fuel, create Green Jobs, reduce the environmental impact of fossil fuels and diminish U.S. reliance on foreign oil. This mission statement has so much good stuff in it I don̢۪t ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$7,500 | 24,387 | |
Max Profit: 0.06 % | Gain at close: -6.19 % |
Mybestpicksever - TRDX,BRKM,AEFI,SOLU,SOPV updateFeb 09, 2011 13:49Hello members, Here is our update for the 5 Power plays we suggested 3 days ago for your review, and as you can see we SMOKED IT AGAIN! All made money except BRKM the jury is still out on that one.. We believe in providing our members with WINNING penny picks. Congratulations to all of our subscribers who have received our free newsletter and have invested in our picks, get ready for yet another great play comming your way real soon ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % | |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % | |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % | |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % |
Mybestpicksever - BRKM our Biodiesel playFeb 07, 2011 08:43Hello members, The Green sector is Hot and we have found a company that is ready to emerge as a leader in an industry and location that is ready to explode!!!!!!!!!!!!!!! The biodiesel sector is heating up again, especially with current legislation extending tax credits and subsidizing costs of up to $1.00 a gallon. BookMerge Technology (BRKM) is an alternative fuel and recycling company. The company's ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % |
http://www.otcmarkets.com
- Website:http://www.extremebiodiesel.com
- Email: info@extremebiodiesel.com
business description
BookMerge Technology is an alternative fuel and recycling company. Our mission is to provide a cost-effective, high-quality alternative diesel fuel, create "green" jobs, reduce the environmental impact of fossil fuels and diminish US reliance on foreign oil. On November 29, 2010 BookMerge aquired ExtremeGreen Technologies, Inc. dba Extreme Biodiesel to fulfill that mission. Extreme Biodiesel is a fully licensed and permitted Biodiesel producer operating in Corona, CA. Our facility has been an operating since January 2008, producing Biodiesel fuel (diesel fuel made from waste vegetable we collect), manufacturing personal biodiesel processors, and the recently added restaurant brown grease recycling service.
23,373,500 per Lucy
BRKM Security Details
Share Structure
Market Value1 $2,513,247 a/o Jan 03, 2012 Shares Outstanding 114,238,500 a/o Sep 30, 2011 Float 13,373,000 a/o Dec 01, 2010 Authorized Shares 200,000,000 a/o Dec 01, 2010 Par Value 0.001
Shareholders
Shareholders of Record 102 a/o Oct 06, 2011
Corporate Actions
Ex. Date Record Date Pay Date Dividend (0.00) Feb 26, 2010 Feb 25, 2010 Feb 25, 2010
Security Notes
- Capital Change=shs increased by 7 for 1 split. Ex-date=02/26/2010. Rec date=02/25/2010. Pay date=02/25/2010.
Short Selling Data
Short Interest 0 (-100%)
Jul 29, 2011 Significant Failures to Deliver No
Transfer Agent(s)
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Filer Audited Financials Not Available Latest Report Not Available Regulatory Agency Not Available CIK 0001440280 Fiscal Year End 6/30 OTC Market Tier OTCQB
Profile Data
SIC - Industry Classification 3433 - Heating equipment, except electric Business Status Development Stage Company a/o Dec 01, 2010 Incorporated In: NV, USA Year of Inc. 2007 Employees 3 a/o Dec 01, 2010
Company Officers
Richard B. Carter President, CEO, CFO Joe Spadafore Corporate Secretary
Company Directors
Richard B. Carter Joe Spadafore
Company Notes
- Formerly=Bigwest Environmental Inc. until 2-2010
BRKM Security Details
Share Structure
| Market Value1 | $2,513,247 | a/o Jan 03, 2012 |
| Shares Outstanding | 114,238,500 | a/o Sep 30, 2011 |
| Float | 13,373,000 | a/o Dec 01, 2010 |
| Authorized Shares | 200,000,000 | a/o Dec 01, 2010 |
| Par Value | 0.001 |
Shareholders
| Shareholders of Record | 102 | a/o Oct 06, 2011 |
Corporate Actions
| Ex. Date | Record Date | Pay Date | |
| Dividend (0.00) | Feb 26, 2010 | Feb 25, 2010 | Feb 25, 2010 |
Security Notes
|
Short Selling Data
| Short Interest | 0 (-100%) Jul 29, 2011 |
| Significant Failures to Deliver | No |
Transfer Agent(s)
Financial Reporting/Disclosure
| Reporting Status | U.S. Reporting: SEC Filer |
| Audited Financials | Not Available |
| Latest Report | Not Available |
| Regulatory Agency | Not Available |
| CIK | 0001440280 |
| Fiscal Year End | 6/30 |
| OTC Market Tier | OTCQB |
Profile Data
| SIC - Industry Classification | 3433 - Heating equipment, except electric |
| Business Status | Development Stage Company a/o Dec 01, 2010 |
| Incorporated In: | NV, USA |
| Year of Inc. | 2007 |
| Employees | 3 a/o Dec 01, 2010 |
Company Officers
| Richard B. Carter | President, CEO, CFO |
| Joe Spadafore | Corporate Secretary |
Company Directors
| Richard B. Carter | |
| Joe Spadafore |
Company Notes
- Formerly=Bigwest Environmental Inc. until 2-2010
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8274281
The aggregate market value of the registrant’s $0.001 par value common equity held by non-affiliates of the registrant was $1,325,859; this is based upon the last trade of the common stock at $0.35 on October 18, 2010. The Registrant had outstanding 80,090,500 shares of Common Stock.
As of October 25, 2010 there were 80,090,500 common shares par value $0.001 issued and outstanding.
(horribly outdated)OTC Disclosure last 10Q reported ___ period ending ___
On October 7, 2010 the Company, as Book Merge Technology, Inc, (BMT), entered into a plan of reorganization with a private company, Extreme Green Technologies Inc. (EGT). A reverse merger was effected on October 11, 2010, wherein BMT, (then a shell), was the surviving company and legal acquirer whereas EGT was the operating company. Accordingly, operations of the entity are reported as those of the original EGT, the operating company. BMT subsequently changed its name to Extreme Green Technologies, Inc., on August 12, 2011.
why hasnt it been updated anywhere???
a hole
| Employees | 3 a/o Dec 01, 2010 |
weeeeeeeeeeeee
line 10 of 10Q
The Company has potentially dilutive securities outstanding as of September 30, 2011 in the form of convertible debt. However the conversion would be anti dilutive, since the Company is in a loss position, and was therefore not considered in the calculation of earnings per share.
The following is a reconciliation of the numerator and denominator of the basic and diluted earnings per share computations for the three months ended September 30, 2011 and 2010:
Capital Structure
Common Stock
On September 1, 2011, 10,000,000 shares of common stock were issued in reducing the deferred investment loans by $10,000.
As at September 30, 2011 the Company was authorized to issue 200,000,000 common shares, of which 114,238,500 were issued and outstanding at September 30, 2011 and 80,090,500 at September 30, 2010.
Shareholders of Record 235 a/o Nov 15, 2011
Before You Invest - Investigate! Always do your own due diligence[/b]
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, __ website
The promoter didnt even have the correct information about the share structure and float which I easily obtained by contacting the transfer agent. I highlighted one of my number one red flags in the comapany description which is...... Our mission is to..... which means we arent really doing anything but we want to..... The last promotion this company had one of the owners accounted for 50% of the stock sold during the promotion.... Can you say DILUTION? On a sinking ship, the first ones to jump off are the RATS. The float the promoter listed was a mere 10 million less than the actual float which is a pretty significant difference when trying to attract investors. What I am getting at again is.... dont trust every alert or shined up due diligence piece you see. Scrutinize it yourself and see the differences in the actual due diligence and what the promoter is putting out. Dont buy the smoke and mirrors! Until tomorrow have an awesome day!
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Subscribe to:
Posts (Atom)